Kyoko Ohno-Matsui, EURETINA 2022: Anomalies of choroidal venous structures in high myopia
In this interview on her EURETINA presentation, Prof. Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) discussed choroidal venous structures and how they change in myopic eyes.
‘Anomalies of choroidal venous structures in high myopia’ was presented at EURETINA 2022, 1–4 September 2022
- What is known about the choroidal structures in myopic eyes? (00:20)
- What were the aims, design and eligibility criteria of your study? (01:07)
- What changes were found in highly myopic eyes? (01:55)
- What is the clinical significance of these findings? (02:35)
Disclosure: Kyoko Ohno-Matsui has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed as a highlight of EURETINA 2022.
Share this Video
Related Videos In Retina/Vitreous
David Boyer, ARVO 2023: Phase IIb RESTORE trial: MCO-010 optogenetic therapy for vision restoration in patients with retinitis pigmentosa
The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]
David Boyer, ARVO 2023: Retinitis Pigmentosa and the unmet needs in its treatment
Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]
Carl Regillo, Hawaiian Eye and Retina 2023: New and emerging treatments for neovascular age-related macular degeneration
It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!